KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Non-Current Liabilities: 2017-2024

Historic Total Non-Current Liabilities for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $2.4 billion.

  • Amneal Pharmaceuticals' Total Non-Current Liabilities rose 15.86% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year increase of 15.86%. This contributed to the annual value of $2.4 billion for FY2024, which is 5.79% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Total Non-Current Liabilities of $2.4 billion as of FY2024, which was down 5.79% from $2.6 billion recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $3.0 billion for FY2020, and its period low was $2.4 billion during FY2024.
  • Its 3-year average for Total Non-Current Liabilities is $2.6 billion, with a median of $2.6 billion in 2023.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Total Non-Current Liabilities increased by 7.36% in 2020, and later declined by 9.62% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $3.0 billion in 2020, then declined by 3.16% to $2.9 billion in 2021, then decreased by 1.42% to $2.8 billion in 2022, then fell by 9.62% to $2.6 billion in 2023, then dropped by 5.79% to $2.4 billion in 2024.